



Clomiphene Citrate with Estradiol Valerate versus Clomiphene Only in Treatment of Women with Unexplained Infertility: Randomized Controlled Trial

Thesis

*Submitted for partial fulfillment of Master Degree In **Obstetrics and Gynaecology***

By

Enas Mohsen EL-Asklany

M.B., B.Ch.-Kasr ELainy-November 2012

Resident of Obstetrics and Gynaecology – EL-Tahrir General Hospital

Under Supervision of

Prof. Hassan Awwad Bayoumy mustafa

Professor of Obstetrics and Gynaecology

Faculty of Medicine – Ain Shams University

Assistant Prof. Mostafa Fouad Gomaa

Assistant Professor of Obstetrics and Gynaecology

Faculty of Medicine – Ain Shams University

Dr. Ahmed Abdelshafy El Shahawy

Lecturer of Obstetrics and Gynaecology

Faculty of Medicine – Ain Shams University

*Faculty of Medicine
Ain Shams University*

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا نك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the
Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound
gratitude to **Prof. Hassan Awwad Bayoumy Mustafa**,
Professor of Obstetrics and Gynaecology Faculty of Medicine –
Ain Shams University for his keen guidance, kind supervision,
valuable advice and continuous encouragement, which made
possible the completion of this work.*

*I am also delighted to express my deepest gratitude and
thanks to **Assistant Prof. Mostafa Fouad Goma**,
Assistant Professor of Obstetrics and Gynaecology Faculty of
Medicine – Ain Shams University, for his kind care, continuous
supervision, valuable instructions, constant help and great
assistance throughout this work.*

*I am deeply thankful to **Dr. Ahmed Abdelshafy El
Shahawy**, Lecturer of Obstetrics and Gynaecology Faculty of
Medicine – Ain Shams University, for his great help, active
participation and guidance.*

Enas Mohsen

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations.....	v
Protocol	
Introduction	1
Aim of the Work.....	5
Review of Literature	
Unexplained Infertility	6
Management of Unexplained Infertility	30
Clomiphene Citrate and Estradiol Valerate	41
Patients and Methods.....	65
Results	75
Discussion	101
Summary	111
Conclusion	118
Recommendations	119
References	120
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Demographic characteristics among the studied groups	77
Table (2):	Basal hormonal profile among the studied groups	78
Table (3):	Endometrial thickness (mm) among the studied groups	79
Table (4):	Ovulation among the studied groups	80
Table (5):	Follicular number and size in ovulated cases among the studied groups.....	81
Table (6):	Serum progesterone (ng/mL) on the day of HCG administration among the studied groups	83
Table (7):	Chemical pregnancy among the studied groups	84
Table (8):	Period from administration of CC and CC+EV to achieve chemical pregnancy	85
Table (9):	Clinical pregnancy among the studied groups	87
Table (10):	Abortion in clinical pregnancy cases among the studied groups	88
Table (11):	Live birth among the studied groups	89
Table (12):	Side effects among the studied groups.....	90
Table (13):	Effect of different variables on clinical pregnancy among estradiol group.....	92
Table (14):	Effect of different variables on clinical pregnancy among clomiphene group	95
Table (15):	Regression model for factors affecting clinical pregnancy	98

List of Tables Cont...

Table No.	Title	Page No.
Table (16):	Prognostic performance of regression model in prediction of clinical pregnancy	99
Table (17):	Prognostic characteristics of regression model in prediction of clinical pregnancy.....	100

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Flow chart of the studied cases.	76
Figure (2):	Endometrial thickness among the studied groups.	79
Figure (3):	Ovulation among the studied groups.	80
Figure (4):	Follicular number among the studied groups.	82
Figure (5):	Follicular size among the studied groups.	82
Figure (6):	Serum progesterone (ng/mL) on the day of HCG administration among the studied groups.	83
Figure (7):	Chemical pregnancy among the studied groups.	84
Figure (8):	Period from administration of CC and CC+EV to achieve chemical pregnancy.	85
Figure (9):	Kaplan meire curve for chemical pregnancy among the studied groups.	86
Figure (10):	Clinical pregnancy among the studied groups.	87
Figure (11):	Abortion in clinical pregnancy cases among the studied groups.	88
Figure (12):	Live birth among the studied groups.	89
Figure (13):	Side effects among the studied groups.	91
Figure (14):	Effect of age on clinical pregnancy among estradiol group.	93
Figure (15):	Effect of BMI on clinical pregnancy among estradiol group.	93
Figure (16):	Effect of E2 on clinical pregnancy among estradiol group.	94

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (17):	Effect of progesterone on clinical pregnancy among estradiol group.....	94
Figure (18):	Effect of age on clinical pregnancy regarding among clomiphene group.	96
Figure (19):	Effect of BMI on clinical pregnancy among clomiphene group.	96
Figure (20):	Effect of E2 on clinical pregnancy among clomiphene group.....	97
Figure (21):	Effect of progesterone on clinical pregnancy among clomiphene group.....	97
Figure (22):	ROC curve for regression model in prediction of clinical pregnancy among estradiol group.	99
Figure (23):	ROC curve for regression model in prediction of clinical pregnancy among clomiphene group.....	99

List of Abbreviations

Abb.	Full term
AFC	Antral Follicle Count
Alu	Arthrobacter luteus
AMH	Antimüllerian Hormone
Apo-A1	Apolipoprotein A1
ART	Assisted reproductive techniques
ASRM	American Society for Reproductive Medicine
BBT	Basal body temperature
BMI	Body mass index
CAT	Chlamydia Antibody Test
CC	Clomiphene citrate
CC/UII	Clomiphene citrate with Intrauterine Insemination
CCCT	Clomiphene Citrate Challenge Test
COH	Controlled ovarian hyperstimulation
COH/UII	Controlled ovarian hyperstimulation with Intrauterine Insemination
COS	Controlled ovarian stimulation
CpGs	5'—C—phosphate—G—3'
DNA	Double Stranded Nucleic acid
DOR	Diminished ovarian reserve
E₂	Estradiol
EBM	Endometrial biopsy
EE	Ethinyle Estradiol
ET	Endometrial thickness
EV	Estradiol Valerate
FASTT	Fast Track and Standard Treatment
FET	Frozen Embryo Transfer
FI	Flow Index
FMR1	Fragile X mental retardation 1
FOXO1	Forkhead box 1
FOXO3	Forkhead box 3

List of Abbreviations Cont...

Abb.	Full term
FSH	Follicle stimulating hormone
FXS	Fragile X syndrome
GA	Gestational Age
GnRH	Gonadotropin releasing hormone
HCG	Human chorionic gonadotropin
HFEA	Human Fertilization and Embryology Authority
HIV	Human immunodeficiency virus
HMG	Human menopausal gonadotropins
HSG	Hysterosalpingography
ICSI	Intracytoplasmic sperm injection
IL	interleukin
IUI	Intrauterine insemination
IVF	In vitro fertilization
IVF/ET	In vitro fertilization/embryo transfer
LBR	Live birth rate
LH	Luteinizing hormone
LIF	Leukemia inhibitory factor
LINE-1	Long interspersed element-1
NCR	Natural cytotoxicity receptor
NICE	National Institute for Health and Care Excellence
NK	Natural killer cells
NPV	Negative predictive value
NSAIDs	Non-steroidal anti-inflammatory drugs
OH	Ovarian hyperstimulation
OHSS	Ovarian hyperstimulation syndrome
OS	Ovarian stimulation
P	Progesterone
P/E₂	Progesterone/ Estradiol ratio

List of Abbreviations Cont...

Abb.	Full term
PC6	Proprotein convertase 5/6
PCO	Polycystic ovary
PCOS	Polycystic ovarIAN syndrome
PI	Pulsatility index
pNK	Peripheral natural killer cells
POR	Poor ovarian response
PPV	Positive predictive value
PRL	Prolactin
PV	Per-vaginal
RPL	Recurrent pregnancy loss
SCH	Subclinical hypothyroidism
SD	Standard deviation
SIS	Saline infusion sonography
THL	Transvaginal hydrolaparoscopy
TMX	Tamoxiphen
TSH	Thyroid stimulating hormone
TV/US	Transvaginal ultrasonography
UI	Unexplained infertility
UK	United Kingdom
uNK	Uterine natural killer cells
US	United States
VEGF-C	Vascular endothelial growth factor C
VFI	Vascularization Flow Index
VI	Vascularization Index
WHO	World Health Organization
αvβ3	Alphavbeta3

INTRODUCTION

Infertility is defined as failure to achieve successful pregnancy after 12 months or more of appropriate, timed unprotected intercourse or therapeutic donor insemination (*Practice committee of ASRM, 2013b*). **Unexplained infertility** (UI) is the infertility in the absence of a definable cause despite a thorough evaluation (*Practice Committee of ASRM, 2008; Moghissi and Wallach, 1983*).

About 4–17 % of couples have fertility problems resolve their infertility, but generally there are more cases unreported (*Gibson and Wilkerson, 2017*). Unexplained infertility affects about 15% - 37% of the couples seeking medical advice (*Isaksson and Tiitinen, 2004; Aboulghar et al., 2003*).

The American Society of Reproductive Medicine guidelines for standard infertility evaluation includes semen analysis, assessment of ovulation, tubal patency and uterine abnormalities and, if indicated, tests for ovarian reserve and laparoscopy (*Practice committee of ASRM, 2012a*).

Clinicians should counsel the couples with unexplained infertility about the empiric nature of available treatment options including IVF (*Gunn and Bates, 2016*).

Spontaneous conception rate in couples with unexplained infertility is more than that in couples with defined causes of infertility. It is about 13-15% during the first year of infertility;

and it increases to 35% during the following two years. Furthermore, the rate may reach 80% in young couples during the next three years of unprotected intercourse without any adjuvant therapy. However it decreases dramatically if the infertility duration is more than 3 years or the women are older than 30 years (*Gelbaya et al., 2014; Nardelli et al., 2014*). The goal of the treatment options is to increase the fecundability/month to reach a closer level to that observed in normally fertile couples (*Tapia et al., 2008*).

The probability of pregnancy is increased by superovulation through increasing the oocytes number which is suitable for fertilization. In women with unexplained infertility, (CC), the traditional therapy, has been the first line used for induction of ovulation for more than four decades (*Legro et al., 2012; Pritts, 2010*). In contrast, current evidence suggests that CC may not be beneficial (*NICE, 2013*).

CC is a non-steroidal triphenyl ethylene derivative, has estrogen agonist and antagonist properties, but CC estrogenic agonist properties manifest only when endogenous estrogen levels are very low (*Practice committee of ASRM, 2013a*). CC binds to the estrogen receptors in the hypothalamus, blocking the estrogen negative feedback mechanism. This decreased feedback stimulates normal compensatory mechanisms that changes the secretion pattern of gonadotropin releasing hormone (GnRH), which increases gonadotropin release from

the pituitary, and in turn development of the ovarian follicles stimulated (*Speroff and Fritz, 2005*).

Generally CC is a very well tolerated drug. However, relatively some side effects are common, but rare to be persistent or severe enough to enforce the patient to stop the drug before completing the usual 5-day course or next cycle of treatment (*Practice committee of ASRM, 2013a*). These side effects are mainly due to its antiestrogenic effect, which typically resolve soon after treatment ends (*Purata et al., 2016*).

About 15%-50% of women who receive CC show thin endometrium and non-trilaminar pattern at midcycle (*Begum et al., 2009*). As an explanation, CC has an intrinsic negative effect on the synchronization of glandular development and endometrial stromal maturity by causing glandular density reduction and decreasing the number of vacuolated cells (*Sereepapong et al., 2000; Unfer et al., 2001*). In addition CC has been detected to affect the uterine blood flow and endometrial perfusion (*Hsu et al., 1995; Nakai et al., 2002*), this leads to lower implantation rates (*Zhao et al., 2012*).

The relatively long half-life of CC, which is known to be 5 days, augments these negative effects (*Biljan et al., 2000*).

Consequently, to reverse the anti-estrogenic effect of CC it seems logic to use adjuvant therapies. For this purpose, some investigations have proven a positive role for estrogens as an

adjuvant treatment (*Gerli et al., 2000; Shahin et al., 2009; Unfer et al., 2001*).

In this study, effect of adding EV to CC will be assessed on the clinical pregnancy rate among women with unexplained infertility.